• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 8-A12B filed by Rafael Holdings Inc.

    3/17/25 2:00:38 PM ET
    $RFL
    Real Estate
    Finance
    Get the next $RFL alert in real time by email
    8-A12B 1 ea0234632-8a12b_rafael.htm FOR REGISTRATION OF CERTAIN CLASSES

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    Form 8-A

     

     

     

    FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES

    PURSUANT TO SECTION 12(b) OR (g) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

     

     

    RAFAEL HOLDINGS, INC.

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware   82-2296593

    (State or other jurisdiction of
    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    520 Broad Street, Newark, NJ 07102

    (Address of principal executive offices and zip code)

     

    Securities to be registered pursuant to Section 12(b) of the Act:

     

    Title of each class to be registered  

    Name of each exchange on which each class is to be registered

    Warrants to purchase shares of Class B common stock, par value $0.01 per share   New York Stock Exchange

     

    If this form relates to the registration of a class of securities pursuant to Section 12(b) of the Exchange Act and is effective pursuant to General Instruction A.(c) or (e), check the following box. ☒

     

    If this form relates to the registration of a class of securities pursuant to Section 12(g) of the Exchange Act and is effective pursuant to General Instruction A.(d) or (e), check the following box. ☐

     

    If this form relates to the registration of a class of securities concurrently with a Regulation A offering, check the following box. ☐

     

    Securities Act registration statement file number to which this form relates: 333-282558

     

    Securities to be registered pursuant to Section 12(g) of the Act: None.

     

     

     

     

     

     

    INFORMATION REQUIRED IN REGISTRATION STATEMENT

     

    Item 1. Description of Registrant’s Securities to be Registered.

     

    For a description of the Warrants of the Registrant to be registered hereunder, reference is made to the information provided in the section entitled “Description of Rafael Capital Stock” in the Pre-Effective Amendment No. 4 to the Registration Statement on Form S-4 filed by the Registrant with the Securities and Exchange Commission on February 11, 2025 (File No. 333-282558), including any subsequent amendments thereto (the “Registration Statement”). Such description in such registration statement is deemed to be incorporated herein by reference.

     

    Item 2. Exhibits.

     

    The following exhibits to this registration statement have been filed as exhibits to the Registration Statement and are hereby incorporated by reference herein

     

    Exhibit No.   Description
    3.1   Amended and Restated Certificate of Incorporation of Rafael Holdings, Inc.
    3.2   Third Amended and Restated By-Laws of Rafael Holdings, Inc.
    10.5   Form of Rafael Public Warrant Agreement

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereto duly authorized.

     

      RAFAEL HOLDINGS, INC.
         
    Date: March 17, 2025 By: /s/ William Conkling
        William Conkling
        Chief Executive Officer

     

     

    2

     

    Get the next $RFL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $RFL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $RFL
    SEC Filings

    View All

    SEC Form S-8 filed by Rafael Holdings Inc.

    S-8 - Rafael Holdings, Inc. (0001713863) (Filer)

    1/27/26 4:38:15 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Rafael Holdings, Inc. (0001713863) (Filer)

    1/12/26 4:29:12 PM ET
    $RFL
    Real Estate
    Finance

    SEC Form 10-Q filed by Rafael Holdings Inc.

    10-Q - Rafael Holdings, Inc. (0001713863) (Filer)

    12/11/25 9:46:49 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec Chairman, CEO & President Jonas Howard S bought $16,742,985 worth of Class B Common Stock (13,080,457 units at $1.28) (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    6/9/25 5:19:19 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

    NEWARK, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL) today reported its financial results for the first quarter fiscal year 2026 ended October 31, 2025. "We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease," said Howard Jonas, Chief Executive Officer, Executive Chairman and Chair

    12/11/25 4:01:00 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is continuing at the recommendation of the Data Monitoring Committee (DMC) following their review of prespecified safety and efficacy date at 48 weeks On August 4, 2025, Joshua Fine was elected as the Company's Chief Operating Officer NEWARK, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL), today reported its financial results for the fourth quarter and full fiscal year 2025 ended July 31, 2025. "We are pleased with the continued progress of our pivotal Phase 3 TransportNPC™ study evaluatin

    10/29/25 4:24:40 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

    NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation, Corporate Governance and Nominating Committees. Separately, the Company also announced that Markus Sieger, an existing Board member, will join the Audit Committee as its Chair and has been elected as Lead Independent Director. Stephen Greenberg had served on Rafael's Board since March 2018 bringing with him a wealth of experience, insights, and guidance. Mr. Greenberg had served as a director of Zedge, Inc. f

    10/28/25 4:01:00 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sieger Markus was granted 29,528 units of Class B Common Stock, increasing direct ownership by 16% to 219,710 units (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    1/30/26 4:01:16 PM ET
    $RFL
    Real Estate
    Finance

    Director Weiss Michael J was granted 39,370 units of Class B Common Stock, increasing direct ownership by 38% to 141,861 units (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    1/29/26 1:24:18 PM ET
    $RFL
    Real Estate
    Finance

    Director Stein Mark N was granted 39,370 units of Class B Common Stock, increasing direct ownership by 343% to 50,845 units (SEC Form 4)

    4 - Rafael Holdings, Inc. (0001713863) (Issuer)

    1/29/26 1:23:57 PM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Leadership Updates

    Live Leadership Updates

    View All

    Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

    NEWARK, N.J., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL, NYSE:RFL) sadly announced today the passing of its Lead Independent Director, Stephen Greenberg, and the appointment of Alan Grayson to its Board of Directors. Mr. Grayson will serve on the Compensation, Corporate Governance and Nominating Committees. Separately, the Company also announced that Markus Sieger, an existing Board member, will join the Audit Committee as its Chair and has been elected as Lead Independent Director. Stephen Greenberg had served on Rafael's Board since March 2018 bringing with him a wealth of experience, insights, and guidance. Mr. Greenberg had served as a director of Zedge, Inc. f

    10/28/25 4:01:00 PM ET
    $RFL
    Real Estate
    Finance

    Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 NEWARK, N.J. and GAINESVILLE, Fla., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common

    8/22/24 6:50:00 AM ET
    $CYTH
    $RFL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Finance

    Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

    Cyclo Therapeutics' TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025 Rafael Holdings, Inc. (NYSE:RFL), and Cyclo Therapeutics, Inc. (NASDAQ:CYTH) today announced that they have entered into a definitive merger agreement to combine the two companies to focus on the development of Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1. On consummation of the merger, Rafael Holdings will issue shares of its Class B common stock to Cyclo Therapeutics' shareholders, based on an exchange ratio

    8/22/24 6:50:00 AM ET
    $CYTH
    $RFL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Real Estate
    Finance

    $RFL
    Financials

    Live finance-specific insights

    View All

    Rafael Holdings Provides Update on Rafael Pharmaceuticals' Two Phase 3 Trials of CPI-613® (Devimistat), AVENGER 500 in Metastatic Pancreatic Cancer and ARMADA 2000 in Relapsed or Refractory Acute Myeloid Leukemia

    Phase 3 Clinical Trial in Metastatic Pancreatic Cancer Did Not Meet its Primary Endpoint of Improved Overall Survival Independent Data Monitoring Committee Recommended the Phase 3 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia Be Stopped Due to Lack of Efficacy Rafael Holdings to Host Conference Call Today at 8:00 a.m. ET NEWARK, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc., (NYSE:RFL), a holding company focused on developing novel cancer metabolism therapeutics through its Barer Institute, investment in Rafael Pharmaceuticals, Inc. ("Rafael Pharmaceuticals") as well as other investments in early-stage ventures, today announced that the AVENGER 500 Phas

    10/28/21 7:00:00 AM ET
    $RFL
    Real Estate
    Finance

    $RFL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

    SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

    9/30/24 5:40:03 PM ET
    $RFL
    Real Estate
    Finance

    Amendment: SEC Form SC 13D/A filed by Rafael Holdings Inc.

    SC 13D/A - Rafael Holdings, Inc. (0001713863) (Subject)

    6/18/24 6:12:11 PM ET
    $RFL
    Real Estate
    Finance

    SEC Form SC 13D/A filed by Rafael Holdings Inc. (Amendment)

    SC 13D/A - Rafael Holdings, Inc. (0001713863) (Filed by)

    10/24/23 4:43:18 PM ET
    $RFL
    Real Estate
    Finance